1. What Is the Gastroenterology Drug Market?
The Gastroenterology Drug Market covers the medicines used to treat the gastrointestinal diseases including inflammatory bowel disease comprising Crohn's disease and ulcerative colitis, irritable bowel syndrome, gastroesophageal reflux disease, gastroparesis, hepatitis, and liver fibrosis. The gastrointestinal cancers that the upper and lower GI tract develops are also included. Drug classes encompass the biologic TNF inhibitors, the vedolizumab gut-selective integrin blocker, the IL-12/23 and IL-23 antibodies, and the JAK inhibitors for IBD. The traditional therapies of proton pump inhibitors and aminosalicylates form the foundation of GI disease management. IBD drug development has generated the densest biologic and small molecule pipeline after oncology. Targeted mechanism approvals include the anti-TNF adalimumab and infliximab, the anti-integrin vedolizumab, the anti-IL-12/23 ustekinumab, the selective IL-23 risankizumab, the S1P modulator ozanimod, and the JAK inhibitor upadacitinib. These provide the gastroenterologist with the multiple treatment options across the moderate to severe IBD that previously had only one or two biologic choices. The gastroenterology drug market is being transformed by the IBD drug positioning studies that compare the risankizumab IL-23 selectivity to the ustekinumab IL-12/23 and to the anti-TNF biologics in the SEQUENCE head-to-head trial. The trial demonstrated the risankizumab superiority over ustekinumab in Crohn's disease, establishing the IL-23 selective blocker as the preferred induction and maintenance therapy.
2. Gastroenterology Drug Market Size & Forecast
3. Emerging Technologies
- Vedolizumab gut-selective mechanism using the anti-alpha4beta7 integrin antibody blocks the gut-homing lymphocyte migration to the intestinal mucosa without the systemic immunosuppression that the anti-TNF biologics create. The favourable safety profile makes vedolizumab the preferred first biologic for the IBD patient with safety concerns about systemic immunosuppression, particularly for the older patient or the patient with recurrent infections. The tuberculosis reactivation and the serious infection risk that anti-TNF therapy creates is avoided with the gut-selective mechanism that vedolizumab provides.
- GEMINI and VISIBLE trials demonstrated vedolizumab clinical remission in 40 to 50 percent of Crohn's disease and ulcerative colitis patients at one year with the durable response that the 12-month open-label extension shows. The gut-selective integrin blocker has established itself as the long-term maintenance therapy for IBD. The IBD treatment target now requires mucosal healing and clinical remission beyond the symptom control that the clinical response endpoint previously accepted. Vedolizumab achieves this higher standard of remission in a meaningful proportion of patients.
- Risankizumab SEQUENCE trial demonstrated superiority over ustekinumab in Crohn's disease clinical remission at 24 weeks in the head-to-head trial that compared the two IL-23 pathway biologics. Risankizumab selectively targets the p19 subunit of IL-23 while ustekinumab targets the shared p40 subunit of both IL-12 and IL-23. The IL-23 p19 selective approach achieves higher remission rates than the IL-12 co-inhibition that ustekinumab adds to the IL-23 blockade.
- IBD positioning algorithm evolution has replaced the step-up therapy starting with aminosalicylates and steroids before escalating to the biologic with the treat-to-target strategy. Early biologic use in the moderate to severe IBD patients is the current standard. The early biologic use targets the prevention of the bowel damage that the inflammatory cascade creates in the untreated or inadequately treated IBD. The therapeutic goal has shifted from symptom control to mucosal healing and transmural remission that only early intensive therapy can achieve.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Specialty Drug Market.
4. Key Market Opportunity
Meaningful upside in the Gastroenterology Drug market involves MASH drug development, where resmetirom's approval and a broad pipeline of GLP-1-based and thyroid hormone receptor agonist approaches target the large MASH patient population with fibrosis risk. Companies with approved or advancing MASH therapies capture a newly created large market. A parallel growth driver is driven by IBD next-generation mechanisms beyond anti-TNF. As MASH drugs launch and IBD mechanisms expand, the addressable opportunity is growing from established acid suppression and IBD anti-TNF revenue toward the large newly addressable MASH and next-generation IBD categories.
5. Top Companies in the Gastroenterology Drug Market
The following organisations hold leading positions in the Gastroenterology Drug Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- AbbVie
- Johnson and Johnson
- Takeda
- Pfizer
- Eli Lilly
- Bristol-Myers Squibb
- Roche
- AstraZeneca
- Bausch Health
- Astellas Pharma
- Phathom Pharmaceuticals
- Eisai
6. Market Segmentation
The Gastroenterology Drug Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Indication | IBDIBSGERDNASHHepatic |
| By Drug Class | Anti-TNFIL-12/23 InhibitorJAK InhibitorPPIGLP-1 for NASH |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Gastroenterology Drug Market trajectory over the forecast period:
Risankizumab SEQUENCE Trial Superiority Over Ustekinumab in Crohn's Disease Remission Has Established the IL-23 p19 Selective Blocker as the Clinically Differentiated Mechanism That Achieves Higher Remission Rates Than IL-12 Co-Inhibition.AbbVie's risankizumab Skyrizi demonstrated endoscopic remission in 40.6% of Crohn disease patients versus 11.9% for placebo at 52 weeks in ADVANCE and MOTIVATE, with a clinical durability that exceeds the 30-35% endoscopic remission rates reported for vedolizumab and ustekinumab. Johnson and Johnson's guselkumab and Tremfya maintained 12-week skin clearance rates above 80% in psoriasis while demonstrating 45-48% clinical remission in ulcerative colitis in QUASAR, creating commercial momentum across dermatology and gastroenterology prescribers simultaneously. The mechanism of selective p19 IL-23 subunit inhibition that spares the IL-12 pathway avoids the theoretical infection risk associated with dual IL-12/23 blockade and maintains type-1 interferon responses that provide viral immunity.
Vedolizumab Gut-Selective Alpha4Beta7 Integrin Blockade Without Systemic Immunosuppression Providing the Safety Profile That Makes It the Preferred First Biologic for IBD Patients With Infection Risk, Older Age, or Tuberculosis Reactivation Concerns.AbbVie's upadacitinib demonstrated 26% clinical remission in moderately-to-severely active Crohn disease at 12 weeks in U-EXCEL with a safety profile driven by the JAK1-selectivity that reduces JAK2 and JAK3-mediated haematopoietic and immune effects associated with non-selective JAK inhibitors. The JAK inhibitor class-wide cardiovascular and malignancy labelling in the over-50 cardiovascular-risk population creates the primary prescribing limitation in IBD, where the target population skews younger and lower-risk than the rheumatoid arthritis patients where the ORAL Surveillance safety signal originated. Pfizer's etrasimod sphingosine-1-phosphate modulator provides a mechanistically distinct oral option in ulcerative colitis that achieves gastrointestinal tissue lymphocyte retention without JAK pathway effects.
IBD Treat-to-Target Strategy Requiring Mucosal Healing and Clinical Remission as the Endpoint Has Replaced Step-Up Therapy With Early Biologic Use in Moderate to Severe IBD Patients Who Are at Risk of the Bowel Damage That Delayed Treatment Allows.Takeda's vedolizumab Entyvio demonstrated superior mucosal healing and clinical remission maintenance to adalimumab in VARSITY head-to-head UC trial, and real-world cohort data consistently shows lower rate of serious infections including opportunistic infections versus systemic biologics that are clinically meaningful in IBD patients with significant comorbidity, prior malignancy, or high infection risk. The gut-selective mechanism restricts lymphocyte migration blockade to the gastrointestinal mucosal vasculature, maintaining systemic immune surveillance that TNF inhibitors and systemic JAK inhibitors cannot preserve. The GEMINI long-term safety dataset of over 2,500 patient-years provides one of the most extensive safety track records among approved IBD biologics and supports prescribing in patients where infection risk makes systemic immunosuppression concerning.
For related market intelligence, see the Pharmaceutical Market.
8. Segmental Analysis
By indication, the inflammatory bowel disease segment dominated the Gastroenterology Drug Market in 2025, as biologics from AbbVie, Johnson and Johnson, and Takeda anchored treatment of Crohn disease and ulcerative colitis, generating the largest share of gastroenterology revenue.
By drug class, the interleukin-23 inhibitor segment is projected to register the highest growth rate through 2034, as AbbVie's Skyrizi and Johnson and Johnson's Tremfya expand across inflammatory bowel disease on superior remission data, displacing older tumour necrosis factor agents in a large treated population.
9. Regional Analysis
Regional demand patterns across the Gastroenterology Drug Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Gastroenterology Drug Market in 2025, accounting for approximately 45% of global revenue, due to the US premium pricing for IBD biologics and the first MASH drug launch at Madrigal and the concentration of gastroenterology drug companies. Moreover, MASH diagnosis and treatment infrastructure is most advanced in the US. In addition, IBD biologic adoption is mature and sustained. Regional dominance is attributed to this combination of pricing environment and MASH leadership.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Gastroenterology Drug Market through 2034, driven by the large IBD, NASH, and hepatic disease patient populations in China, Japan, and Southeast Asia and expanding pharmaceutical access and reimbursement. The region is also witnessing MASH drug adoption growing with metabolic disease awareness. Moreover, IBD biologic adoption is expanding. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Gastroenterology Drug Market was valued at USD 56.86 Bn in 2025 and is projected to reach USD 100.22 Bn by 2034, growing at a CAGR of 6.5% over the 2026–2034 forecast period.
The Gastroenterology Drug Market is projected to grow at a CAGR of 6.5% from 2026 to 2034.
North America dominated the Gastroenterology Drug Market in 2025, accounting for approximately 45% of global revenue, due to the US premium pricing for IBD biologics and the first MASH drug launch at Madrigal and the concentration of gastroenterology drug companies.
The leading companies in the Gastroenterology Drug Market include AbbVie, Johnson and Johnson, Takeda, Pfizer, Eli Lilly, Bristol-Myers Squibb, Roche, AstraZeneca, Bausch Health, Astellas Pharma, Phathom Pharmaceuticals, Eisai.
Risankizumab sequence trial superiority over ustekinumab in crohn's disease remission has established the il-23 p19 selective blocker as the clinically differentiated mechanism that achieves higher remission rates than il-12 co-inhibition.
By indication, the inflammatory bowel disease segment dominated the Gastroenterology Drug Market in 2025, as biologics from AbbVie, Johnson and Johnson, and Takeda anchored treatment of Crohn disease and ulcerative colitis, generating the largest share of gastroenterology revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.